This evening we watched BridgeBio Pharma rise 1.7% to a price of $35.01 per share. The small-cap Pharmaceutical company is now trading -22.95% below its average target price of $45.44. Analysts have set target prices ranging from $33.0 to $51.0 per share for BridgeBio Pharma, and have given the stock an average rating of buy.
The stock has an unusually large proportion of its shares sold short at 15.9%, and a short ratio of 6.34. Since 6.24% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 95.5% of BridgeBio Pharma's shares being owned by this investor type.
Institutions Invested in BridgeBio Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Kohlberg Kravis Roberts & Co. L.P. | 19% | 31,060,971 | $1,087,444,542 |
| 2023-03-31 | Viking Global Investors, L.P. | 16% | 26,620,991 | $932,000,850 |
| 2023-03-31 | Vanguard Group Inc | 7% | 12,063,256 | $422,334,572 |
| 2023-03-31 | Blackrock Inc. | 6% | 9,117,781 | $319,213,497 |
| 2023-03-31 | Aisling Capital Management LP | 4% | 6,068,125 | $212,445,046 |
| 2023-03-31 | State Street Corporation | 3% | 5,143,013 | $180,056,876 |
| 2023-03-31 | Cormorant Asset Management, LP | 3% | 4,557,414 | $159,555,056 |
| 2023-03-31 | HHLR Advisors, LTD | 2% | 3,978,410 | $139,284,127 |
| 2023-03-31 | Laurion Capital Management, LP | 2% | 3,512,759 | $122,981,686 |
| 2023-03-31 | American International Group, Inc. | 2% | 2,704,374 | $94,680,129 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on BridgeBio Pharma.
